The University of Geneva and Modex Therapeutics Ltd (Lausanne) have announced that they have signed an exclusive license agreement for worldwide rights to a breakthrough technology developed in the laboratory of Professor Beat Imhof at the University of Geneva.
The licensed technology covers a unique family of small peptide molecules that can be used to modulate the location and number of melanocytes in the epidermis. Melanocytes are cells positioned at the base of the epidermis that are responsible for the pigmentation of skin. A pathological accumulation of melanocytes can lead to serious skin disorders. The discovery was made by Professor Beat Imhof and Dr.Bernhard Wehrle-Haller at the University of Geneva and is covered by an extensive patent application filed worldwide through Unitec, the technology transfer office of the University.
Furthermore, Modex and the University of Geneva have entered into a 3-year collaboration agreement supporting the Laboratory of Professor Imhof to identify other peptides and refine further the application of these topically applied drugs. Modex will also collaborate with leading clinical experts and contract organizations to rapidly prepare dossiers for entry into clinical trials. First clinical applications are targeted at hyper-pigmented skin conditions such as lentigo senilis (age/liver spots) and dysplastic naevi (pre-cancerous melanoma).
Visit
Office of Technology Transfer, University of Geneva: Link
Modex: Link
Geneva region: ideal location for global healthcare and life science companies: Link
Geneva – Crossroads of European biotech: Link
Reducing biotech time-to-market: Lnk
Geneva in healthcare & life sciences: Link
Geneva’s world-class infrastructure and advantages
‘Why high-tech leaders choose Geneva’: Link
US team identifies Geneva’s winning formula - Location, Language, Lifestyle, Labor and Laws : Link
World-class infrastructure: Link
Ideal business location at the heart of Europe: Link
Multiinational companies in Geneva: Link
International organisations in Geneva: Link
